{"date":"2025-04-08","count":16,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-4724-2025-04-08-2148-1oj2zvc","company_id":"4724","company":"宣捷幹細胞","market":"興櫃","industry":"生技醫療","date":"2025-04-08","time":"21:48:41","subject":"代重要子公司育禾管理顧問股份有限公司公告會計主管異動","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：宣捷幹細胞（4724），2025-04-08 21:48，「代重要子公司育禾管理顧問股份有限公司公告會計主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6576-2025-04-08-2025-1t1d3xe","company_id":"6576","company":"逸達","market":"上櫃","industry":"生技醫療","date":"2025-04-08","time":"20:25:19","subject":"美國對等關稅政策對本集團營運無重大影響","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：逸達（6576），2025-04-08 20:25，「美國對等關稅政策對本集團營運無重大影響」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6936-2025-04-08-1944-10apgwn","company_id":"6936","company":"永鴻生技","market":"上市","industry":"生技醫療","date":"2025-04-08","time":"19:44:10","subject":"公告本公司股票初次上市前現金增資認股繳款期間暨暫定承銷價相關事宜","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：永鴻生技（6936），2025-04-08 19:44，「公告本公司股票初次上市前現金增資認股繳款期間暨暫定承銷價相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6610-2025-04-08-1705-1hjpfjx","company_id":"6610","company":"安成生技","market":"興櫃","industry":"生技醫療","date":"2025-04-08","time":"17:05:36","subject":"公告本公司用於治療單純型遺傳性表皮分解性水皰症（EBS）之開發中新藥AC-203，獲得印度同意進行第二/三期人體臨床試驗。","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：安成生技（6610），2025-04-08 17:05，「公告本公司用於治療單純型遺傳性表皮分解性水皰症（EBS）之開發中新藥AC-203，獲得印度同意進行第二/三期人體臨床試驗」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6547-2025-04-08-1702-1bnacgi","company_id":"6547","company":"高端疫苗","market":"上櫃","industry":"生技醫療","date":"2025-04-08","time":"17:02:54","subject":"公告高端疫苗生物製劑股份有限公司國內第一次無擔保(例：第一次有擔保)轉(交)換公司債(簡稱：高端疫苗一，代碼：65471)停止受理轉交換及到期日落於停止轉(交)換期間等相關事項。","clause":"第53款","fact_date":"2025-04-08","cite_as":"公開資訊觀測站重大訊息：高端疫苗（6547），2025-04-08 17:02，「公告高端疫苗生物製劑股份有限公司國內第一次無擔保(例：第一次有擔保)轉(交)換公司債(簡稱：高端疫苗一，代碼：65471」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6936-2025-04-08-1655-qkrt5g","company_id":"6936","company":"永鴻生技","market":"上市","industry":"生技醫療","date":"2025-04-08","time":"16:55:45","subject":"公告本公司股務代理機構名稱、辦公處所及聯絡電話","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：永鴻生技（6936），2025-04-08 16:55，「公告本公司股務代理機構名稱、辦公處所及聯絡電話」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6936-2025-04-08-1655-1dgvjpk","company_id":"6936","company":"永鴻生技","market":"上市","industry":"生技醫療","date":"2025-04-08","time":"16:55:24","subject":"公告本公司股票初次上市現金增資股款委託代收及存儲價款機構","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：永鴻生技（6936），2025-04-08 16:55，「公告本公司股票初次上市現金增資股款委託代收及存儲價款機構」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2025-04-08-1654-a8ml5z","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2025-04-08","time":"16:54:15","subject":"公告本公司董事會通過現金增資發行新股(通過變更發行股數)","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2025-04-08 16:54，「公告本公司董事會通過現金增資發行新股(通過變更發行股數)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2025-04-08-1649-1g6i233","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2025-04-08","time":"16:49:32","subject":"公告本公司董事長異動","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2025-04-08 16:49，「公告本公司董事長異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6534-2025-04-08-1601-xwssao","company_id":"6534","company":"正瀚-創","market":"上市","industry":"生技醫療","date":"2025-04-08","time":"16:01:56","subject":"公告本公司取得會計師113年內部控制專案審查報告","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：正瀚-創（6534），2025-04-08 16:01，「公告本公司取得會計師113年內部控制專案審查報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4167-2025-04-08-1544-e8coqg","company_id":"4167","company":"松瑞藥","market":"上櫃","industry":"生技醫療","date":"2025-04-08","time":"15:44:39","subject":"公告本公司厄他培南針劑產品獲得中國核准上市並取得藥證","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：松瑞藥（4167），2025-04-08 15:44，「公告本公司厄他培南針劑產品獲得中國核准上市並取得藥證」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6645-2025-04-08-1405-ois9r3","company_id":"6645","company":"金萬林-創","market":"上市","industry":"生技醫療","date":"2025-04-08","time":"14:05:50","subject":"公告本公司初次申請股票創新板上市時所出具之承諾事項暨其後續執行情形","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：金萬林-創（6645），2025-04-08 14:05，「公告本公司初次申請股票創新板上市時所出具之承諾事項暨其後續執行情形」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7762-2025-04-08-0853-1gagpws","company_id":"7762","company":"吉晟生","market":"興櫃","industry":"生技醫療","date":"2025-04-08","time":"08:53:24","subject":"美國對等關稅措施對本公司營運無重大影響說明","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：吉晟生（7762），2025-04-08 08:53，「美國對等關稅措施對本公司營運無重大影響說明」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6541-2025-04-08-0151-1aou8b6","company_id":"6541","company":"泰福-KY","market":"上市","industry":"生技醫療","date":"2025-04-08","time":"01:51:33","subject":"公告本公司任命營運副總經理","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：泰福-KY（6541），2025-04-08 01:51，「公告本公司任命營運副總經理」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6541-2025-04-08-0151-rfxofl","company_id":"6541","company":"泰福-KY","market":"上市","industry":"生技醫療","date":"2025-04-08","time":"01:51:07","subject":"公告本公司任命商務長","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：泰福-KY（6541），2025-04-08 01:51，「公告本公司任命商務長」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6541-2025-04-08-0150-1giceg5","company_id":"6541","company":"泰福-KY","market":"上市","industry":"生技醫療","date":"2025-04-08","time":"01:50:37","subject":"公告本公司董事會決議通過辦理現金增資發行新股案","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：泰福-KY（6541），2025-04-08 01:50，「公告本公司董事會決議通過辦理現金增資發行新股案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}